NG11-2 Phase-Ib Dose Escalation Phase Completes & Dose Expansion Cohort Open to Enrolment Gallery NG11-2 Phase-Ib Dose Escalation Phase Completes & Dose Expansion Cohort Open to Enrolment By Chloe Atkinson|2024-12-05T11:10:16+00:00March 4th, 2024|Clinical Development, News, NG11| Read More
VasoDynamics initiates NG13 optimisation development with key appointment Gallery VasoDynamics initiates NG13 optimisation development with key appointment By Chloe Atkinson|2024-12-05T11:09:11+00:00February 8th, 2024|Clinical Development, Corporate Development, News, NG13| Read More
Labour Shadow Health Team Visit Stevenage Bioscience Catalyst and Discuss VasoDynamics’ Technology Gallery Labour Shadow Health Team Visit Stevenage Bioscience Catalyst and Discuss VasoDynamics’ Technology By Bradley Shaw|2025-08-05T11:05:01+00:00February 7th, 2024|News| Read More
NG11-2 Phase-Ib Dose Escalation Clinical Study Progresses to Final Dose Level Gallery NG11-2 Phase-Ib Dose Escalation Clinical Study Progresses to Final Dose Level By Chloe Atkinson|2025-02-17T12:40:59+00:00December 21st, 2023|Clinical Development, News, NG12| Read More
VasoDynamics files global patent (PCT) for the methods to select patients for the clinical studies on radiation-induced oral mucositis Gallery VasoDynamics files global patent (PCT) for the methods to select patients for the clinical studies on radiation-induced oral mucositis By Chloe Atkinson|2025-05-20T09:41:00+00:00November 7th, 2023|News| Read More
NG11-2 Phase Ib Dose Escalation Clinical Study Progressing through Dose Levels Gallery NG11-2 Phase Ib Dose Escalation Clinical Study Progressing through Dose Levels By Chloe Atkinson|2025-05-20T09:39:47+00:00October 16th, 2023|Clinical Development, News, NG11| Read More
VasoDynamics strengthens management team with key appointments Gallery VasoDynamics strengthens management team with key appointments By Chloe Atkinson|2025-02-17T12:37:11+00:00August 1st, 2023|Corporate Development, News| Read More
First dose cohort completed and enrolment to second dose cohort commenced in NG11-2 Phase-Ib clinical trial Gallery First dose cohort completed and enrolment to second dose cohort commenced in NG11-2 Phase-Ib clinical trial By Chloe Atkinson|2025-05-20T09:40:01+00:00July 28th, 2023|Clinical Development, News, NG11| Read More
First patient dosed for the first week in NG11-2 Phase Ib clinical trial Gallery First patient dosed for the first week in NG11-2 Phase Ib clinical trial By Chloe Atkinson|2025-02-17T11:59:27+00:00May 26th, 2023|Clinical Development, News, NG11| Read More
First patient enrolled in NG11-2 Phase Ib clinical trial Gallery First patient enrolled in NG11-2 Phase Ib clinical trial By Chloe Atkinson|2025-05-20T09:39:27+00:00May 8th, 2023|Clinical Development, News, NG11| Read More
